Skeletal Manifestations of Hyperparathyroidism by Khedr, Ahmed
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Skeletal Manifestations of Hyperparathyroidism
Ahmed Khedr
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.74034
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Ahmed Khedr
Additional information is available at the end of the chapter
Abstract
The presentation of hyperparathyroidism changed over the last decades which gave rise 
to more variable presentations than before. Hyperparathyroidism has a catabolic effect 
on the skeleton whether the disease is symptomatic or asymptomatic or normocalcemic. 
It is now understood that the effect of parathyroid hormone (PTH) on the bone is medi-
ated by complex interaction between different bone cells and cells of the immune system 
especially T lymphocytes. Protecting the skeletal system against bone loss and pathologi-
cal fractures is among the important treatment goals of hyperparathyroidism. To achieve 
this goal, more complex laboratory tests to monitor the bone turnover and imaging tech-
niques and modalities as high-resolution peripheral quantitative computed tomography 
(HR-pQCT) and trabecular bone score (TBS) are employed. These imaging techniques 
showed the affection of microarchitecture of the cortical and the trabecular bone. For the 
time being, surgery and alendronate treatment are believed to reverse the catabolic effect 
of hyperparathyroidism on the bone. Vitamin D supplementation in case of vitamin D 
deficiency may also has a protective effect on the skeleton.
Keywords: osteitis fibrosa cystica (OFC), bisphosphonates, brown tumor, RANKL, 
parathyroid hormone, bone metabolism
1. Introduction
Over the last hundred years, the effect of parathyroid hormone (PTH) on bone metabolism 
was extensively discussed. PTH acts on the bone cells through several mediators, and its 
action involves a variety of cells. It is now understood that parathyroid hormone has both 
catabolic and anabolic effects on bone metabolism [1]. Mandl in Austria was the first to prove 
that the enlarged parathyroid was responsible for the skeletal manifestations of hyperpara-
thyroidism after the first successful removal of parathyroid adenoma [2]. The clinical picture 
of the disease also changed dramatically over the years from a disease of “stones, bones, 
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abdominal groans, thrones and psychiatric overtone” to a disease which can be only detected 
by elevated calcium and the PTH level on laboratory tests or even the elevated PTH level with 
no hypercalcemia [2, 3]. This change in clinical presentation was accompanied by the intro-
duction of newer lab tests to assess bone turnover and newer imaging techniques to assess 
the bone quality [2]. The treatment modalities also evolved, allowing more individualized 
approach for treating each patient [4].
2. Action of parathyroid hormone on the bone in 
hyperparathyroidism
The main function of PTH is to maintain calcium levels within the normal range thorough 
its action on the bone, kidneys, and intestine. It also decreases serum phosphorous through 
inhibiting renal reabsorption [5, 6]. PTH can produce catabolic or anabolic effect on bone 
metabolism depending on the level of the hormone, periodicity, and duration of exposure 
[6, 7]. Primary hyperparathyroidism (PHPT), continuous PTH infusion (cPTH), and intermit-
tent PTH treatment (iPTH) increase bone turnover in trabecular and cortical bone and elevate 
the markers for bone resorption and formation [2, 8–10]. PHPT and cPTH enhance cortical 
bone loss by increasing osteoclastic activity but produce cancellous bone that is relatively pre-
served or modestly increased [2, 9, 11]. iPTH treatment stimulates trabecular bone formation 
by osteoblast stimulation and can cause small cortical bone loss [12, 13]. The pattern of bone 
loss in PHPT is different from the pattern of bone loss in osteoporosis. In osteoporosis, the 
trabecular bone loss predominates, while in PHPT the cortical bone loss predominates [14].
2.1. Action of parathyroid hormone on bone cells
Normally, bone structural integrity is maintained by the process or remodeling where the 
bone is removed by osteoclasts and new bone is synthesized by osteoblasts [15]. The osteo-
clasts and osteoblasts are arranged in a structure called the basic multicellular unit (BMU). 
A BMU consists of osteoclasts in front with osteoblasts, some blood vessels, and connective 
tissue behind [16, 17]. Osteoclasts are formed by fusion of mononuclear precursors, while 
osteoblasts originate from undifferentiated mesenchymal cells [16, 18]. Parathyroid hormone 
produces its effects by binding to its receptor PPR (also known as PTH-1R). While osteoblasts, 
osteocytes, and lymphocytes, mesenchymal stromal cells express PPR, osteoclasts respond 
indirectly to PTH through various mediators and cytokines produced by cells which carry 
PPR [6, 19–23]. It is now believed that osteocytes are the primary cellular target of PTH in the 
bone. Osteocytes are the main cells that express PPR in the musculoskeletal system [14]. Saini 
et al. designed a study where they generated mice with PPR deletion in osteocytes. These mice 
showed significant increase in bone mineral density (BMD), reduced osteoblast activity, and 
decreased skeletal response to anabolic or catabolic PTH regimen [24]. Other studies also sup-
ported the fact that osteocytes rather than osteoblasts are the main source of the receptor acti-
vator of nuclear factor kappa-B ligand (RANKL) in the process of osteoclastogenesis [25, 26]. 
Where mice lacking RANKL in osteocytes had less bone loss compared to control mice when they 
are exposed to dietary calcium deficiency for 30 days causing secondary hyperparathyroidism. 
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There was less RANKL expression and less osteoclast number in the group of mice lacking 
RANKL [25]. Another study was designed with a co-culture of osteoclast precursors and osteo-
cytes. The study showed that RANKL is provided through dendritic processes of osteocytes 
to osteoclast precursor and that soluble RANKL had less contribution to osteoclastogenesis 
[27]. In humans, the RANKL/osteoprotegerin (OPG) ratio is higher in patients with PHPT than 
controls. This ratio is decreased with parathyroidectomy (PTx) or medical treatment by alen-
dronate [28]. Another study on patients with PHPT showed that RANKL correlated with bone 
resorption markers in these patients and suggested that it can be used to determine patients of 
PHPT with greater risk of bone loss [13]. Another study was conducted on patients with PHPT 
where transiliac bone biopsy was done before PTx and 12 months after surgery and mRNA for 
RANKL and OPG were measured. The study showed that the mRNA ratio of RANKL/OPG 
decreased significantly after surgery [13].
PTH increases RANKL/OPG ratio with continuous exposure to high dose which produces 
catabolic effect as in hyperparathyroidism. This results in increased bone turnover, osteope-
nia, and bone loss in hyperparathyroidism. In addition, several extraskeletal manifestations 
of hyperparathyroidism are due to increased bone catabolism and hypercalcemia as nephro-
lithiasis, renal failure, peptic ulcer, and mental changes [2]. On the other hand, intermittent 
low-dose exposure to PTH has an anabolic effect through the SOST/sclerostin pathway [6].
The OPG-RANK-RANKL pathway is the mechanism by which hyperparathyroidism induces 
bone catabolism. PTH regulates the production of RANKL and its soluble decoy receptor 
OPG by osteoblasts and osteocytes [29–31]. RANKL binds to the receptor activator of nuclear 
factor kappa-B (RANK) on the osteoclast precursor stimulating their differentiation to osteo-
clasts and on the surface of the osteoclasts increasing their bone-resorbing activity. OPG 
inhibits the action of RANKL by binding to RANKL, thus preventing its access to the recep-
tor RANK. In this way, the process of bone resorption is controlled by the balance between 
the concentration of RANKL and OPG [32–36]. In rats, continuous infusion of human PTH 
increased RANKL and RANKL mRNA expression and decreased OPG and OPG mRNA [37]. 
In vitro studies also showed that PTH activates of cAMP/PKA–CREB pathway increase the 
Tnfsf11 gene encoding RANKL, whereas a PTH inhibits the mRNA encoding for OPG expres-
sion through a PKA-CREB-AP-1 pathway [38–40].
2.2. Effect of parathyroid hormone on cells of the bone marrow and cells of the 
immune system
Cells of bone marrow also play a role in the effect of PTH on bone metabolism. Lymphocytes 
are believed to play a role on bone metabolism. T lymphocytes express PPR [23]. T cells express 
RANKL and CD40L on their surface that binds with RANK and CD40 in osteoclast precursors 
and osteoclasts to stimulate them [13, 41, 42]. Th17 cells form a subset of T lymphocytes that con-
tribute to bone resorption. TH17 cells secrete IL-17, RANKL, TNF-α, IL-1, and IL-6, along with 
low levels of IFN-γ which contribute to osteoclastogenesis [43–46]. IL-17 stimulates the secretion 
of RANKL by osteoblasts and osteocytes and upregulates RANK [46, 47]. This is consistent with 
a human study that showed statistically significant elevation of IL-17 in postmenopausal women 
who had osteoporosis when compared with postmenopausal women who had osteopenia [47]. 
It is also noted that cPTH stimulates the production of TGF-β, IL-6, and TNF-α by bone cells and 
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stromal cells [7, 48, 49]. TGF-β and IL-6 direct the differentiation of naive CD4+ cells into TH17 cells 
[50–52]. TNF-α plays also an important role as a mediator of PTH catabolic action. PTH stimulates 
T cells to produce TNF-α. In mice lacking T-cell TNF-α, PTH failed to produce bone resorption but 
did not affect bone formation. Thus, in these mice there was no cortical bone loss, and there was 
increased trabecular bone formation [19]. TNF-α stimulates osteoclast formation and activity by 
multiple mechanisms. TNF-α increases the production of RANKL by osteoblasts and osteocytes. It 
also increases the expression of CD40 by stromal cells and osteoblasts increasing their responsive-
ness to CD40L expressed by T cells. Activation of CD40 on stromal cells and osteoblasts decreases 
the OPG secretion, thus increasing the RANKL/OPG ratio [7].
Bone marrow macrophages also play a role in the action of PTH on the bone. Macrophages 
express PPR. Depletion of the precursors of macrophages decreases the anabolic effect of iPTH 
[19]. The monocyte chemoattractant protein-1 (MCP-1) which is a chemotactic factor for mono-
cyte and macrophages is a mediator for PHT-induced bone resorption [6]. MCP-1 was proven 
to attract pre-osteoclast in in vitro studies, thus increasing bone resorption [53]. It was found 
that the expression for MCP-1 increased by cPTH and iPTH in rat osteoblastic cells. With cPTH 
the MCP-1 expression was sustained, while with the anabolic protocol, the expression of MCP-1 
was transient yet more pronounced. This suggests that the transient increase of bone resorp-
tion may be necessary before the anabolic effect of PTH on the bone [53, 54]. In human studies, 
MCP-1 levels correlate with PTH levels in patients with PHPT. After PTx, the levels of MCP-1 
decreased significantly starting from 15 minutes following parathyroid adenoma removal [55].
3. Skeletal abnormalities in symptomatic hyperparathyroidism
3.1. Incidence
Hyperparathyroidism was first described in 1891 by von Recklinghausen. Despite of the fact that 
primary hyperparathyroidism was classically described as disease of “stones, bones, abdominal 
groans, thrones, and psychiatric overtone,” the presentation of the disease changed dramatically 
over the past decades. Nowadays, the classical presentation with osteitis fibrosa cystica and path-
ological fractures is rarely seen in developed countries. Currently, larger numbers of patients are 
being identified with neuropsychiatric or cardiac manifestation and laboratory studies in the USA 
and Europe [2, 56]. In developing countries, the symptomatic form of PHPT was prevalent for a 
long time, but some countries as Brazil and China are having a shift toward the asymptomatic 
disease. However, other countries as India, Iran, Saudi Arabia, and Thailand still have high preva-
lence of the symptomatic form of the disease with pronounced skeletal manifestations [56–58].
3.2. Clinical manifestations
The signs and symptoms of severe bone disease include bone pain and pathologic fractures. 
Skeletal muscles are also affected by hyperparathyroidism where the patients have proximal 
muscle weakness and hyperreflexia [2, 59].
One of the features of skeletal involvement in hyperparathyroidism is hungry bone syndrome. 
It is characterized by hypocalcemia and hypophosphatemia following PTx. It is thought to be 
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due to withdrawal of osteoclast stimulation by high levels of PTH. This condition is treated 
by high doses of calcium and vitamin D [60, 61].
3.3. Investigations
3.3.1. Imaging
3.3.1.1. Radiography
Plain X-rays can show the classical findings of osteitis fibrosa cystica. This is characterized by 
marked thinning of the cortex (demineralization). Salt and pepper appearance for skull X-rays 
is also seen. Bone resorption of distal third of the clavicle is also seen. Hand X-rays show sub-
periosteal bone erosions in the distal phalanges and the lateral aspects of middle phalanges. 
Lytic lesions can also be seen in the pelvis and long bones with pathological fractures. Lytic 
lesions are referred to as brown tumors; these are a mixture of hemosiderin (hence, the brown 
color on pathological examination), woven bone, fibrous tissue, and osteoclasts. However, the 
lesions are nonneoplastic [2].
3.3.1.2. Bone mineral density
Bone mineral density can be measured by dual energy X-ray absorptiometry (DEXA) scan in 
all patients where measurements should be taken for lumbar spine, hip regions (total hip and 
femoral neck), and distal 1/3 of the radius. It is important to measure the bone mineral density 
in distal radius as it is a cortical site, and hyperparathyroidism is known to have catabolic 
effect on cortical bone [2, 56].
3.3.1.3. High-resolution peripheral quantitative computed tomography (HR-pQCT)
This is a noninvasive technique that allows assessment of the cortical and trabecular bone 
quality in PHPT [56]. HR-pQCT measures volumetric bone density, bone geometry, skel-
etal microarchitecture, and bone strength in the cortical and trabecular compartments. 
HR-pQCT showed that microarchitectural deterioration in both cortical and cancellous sites 
has decreased volumetric densities, more widely spaced, and heterogeneously distributed 
trabeculae and thinner cortices [62–64].
3.3.1.4. Trabecular bone score (TBS)
TBS is obtained from DEXA scan by applying special software. It is a textural analysis that 
provides an indirect index of trabecular microarchitecture. It can differentiate between DEXA 
scans showing similar bone densities. A high TBS is associated with a dense trabecular net-
work and greater bone strength, and a low TBS indicates poor microarchitecture and poor 
strength [65–67].
3.3.2. Histomorphometry
Histomorphometry of transiliac biopsy will show reduced width of the cortex with increased 
porosity, while the trabecular bone is preserved [14].
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3.3.3. Laboratory tests
In severe PHPT, serum calcium and parathormone are elevated. There are special markers for 
bone elevation as osteocalcin, type I procollagen peptide, and alkaline phosphatase. Alkaline 
phosphatase is much above the normal in all cases of hyperparathyroidism with increased 
bone turnover. Markers of bone resorption are also typically elevated PHPT. These include 
deoxypyridinoline, N-telopeptide, and C-telopeptide. These markers are products of break-
down of type 1 collagen [2]. Renal functions and urinary calcium should be evaluated. 25OH 
vitamin D levels should be as lower as the levels of 25OH vitamin D correlate with higher 
bone turnover and lower BMD, and both improve with repletion of 25OH vitamin D [68, 69].
4. Skeletal abnormalities in asymptomatic primary 
hyperparathyroidism
4.1. Manifestations
In 1970s, the wide availability of measurement of serum calcium changed the clinical pre-
sentation of hyperparathyroidism giving rise to the entity of asymptomatic primary hyper-
parathyroidism [14]. These are patients with hypercalcemia and elevated PTH but who are 
discovered accidentally while doing laboratory studies [58]. These patients have no X-ray 
finding of symptomatic hyperparathyroidism previously described [58]. These patients show 
decreased bone mass in cortical sites when measured by DEXA scan. Thus, DEXA scan shows 
reduction of bone mineral density at distal 1/3 of forearm (which is composed primarily of 
cortical bone), while bone density of lumbar spine (which is formed mainly of trabecular 
bone) is preserved. However, bone scan may remain stable for years in patients with asymp-
tomatic hyperparathyroidism. Rubin et al. noted that the BMD of the lumbar spine remained 
stable for 15 years while it started to fall in cortical sites before 10 years [70, 71]. Micro-CT and 
histomorphometric studies show reduction of cortical bone with preservation of cancellous 
bone in PHPT [70, 71]. However, clinical studies showed that patients with hyperparathy-
roidism have higher risk of fractures both at cortical and cancellous sites [72, 73]. HR-pQCT 
helped to resolve this controversy. HR-pQCT showed that microarchitectural deterioration 
in both cortical and cancellous sites has decreased volumetric densities, more widely spaced, 
and heterogeneously distributed trabeculae and thinner cortices [62–64]. These studies also 
highlighted that weight bearing is a factor that can prevent the microarchitectural deteriora-
tion where they showed that the radius is more negatively affected than the tibias [63, 64]. 
Stein et al. performed individual trabecula segmentation that gave an insight into the trabecu-
lar microstructure. They found that the number of plate-like trabeculae is reduced relative 
to the rod-like trabeculae (decrease P-R ratio); there is reduced connectivity and less axially 
aligned trabecular network [64]. Another imaging modality which can show skeletal affection 
in asymptomatic cases is the trabecular bone score (TBS). Romagnoli et al. showed that TBS 
was significantly lower in patients with PHPT compared to controls. Among patients with 
PHPT, TBS was significantly lower in patients with vertebral fractures when compared to 
patients without vertebral fractures [74]. Eller-Vainicher et al. showed that TBS was associated 
with vertebral fractures regardless of age, gender, BMD, and BMI [75].
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4.2. Natural history of bone disease in asymptomatic hyperparathyroidism
Age and female genders are associated with higher fracture risk in PHPT [73]. Currently, it is 
still unclear whether fracture risk assessment tools as FRAX can help to predict risk of fractures 
in patients with PHPT or not [14]. Concerning changes in BMD over time, Rao et al. monitored 
80 patients with asymptomatic PHPT for a mean of 46 month. They did not observe deterio-
ration of biochemical markers nor BMD measurements [74]. Silverberg et al. followed up 121 
patients with PHPT of whom 101 were asymptomatic for up to 10 years. Twenty-five percent of 
patients showed disease progression. They also noted that patients younger than 50 years old 
had more likelihood of disease progression [71]. Rao et al. conducted randomized controlled trial 
on patients with PHPT and concluded that BMD at the hip and spine improves after PTx [76]. 
Rubin et al. studied 116 patients with PHPT of whom 99 were asymptomatic, PTX improved the 
biochemical markers and BMD, and without surgery PHPT progressed in one third of the cases 
[76]. Eller-Vainicher et al. studied 92 patients with PHPT and 98 controls for 24 months. DEXA 
scan and TBS in patients treated surgically and conservatively. In the surgical group, BMD and 
TBS increased significantly although it remained lower than controls. In the conservative group, 
BMD showed a decrease which was not statistically significant, and TBS showed a decrease 
which was not statistically significant; except in three patients who had vertebral fractures, the 
TBS showed a statistically significant decrease [75]. Hansen et al. measured BMD and HR-pQCT 
in women with PHPT before and 1 year after PTx. BMD improved after PTx, and HR-pQCT 
showed improvement of the cortical and trabecular parameters of the radius and tibia [77].
5. Skeletal abnormalities in normocalcemic primary 
hyperparathyroidism
5.1. Manifestations
This is a cohort of patients which includes patients with normal total and ionized calcium but 
elevated PTH in the absence of causes of secondary hyperparathyroidism. This may be due 
to target organ resistance of the bone and kidney, or these patients are in early stages of the 
disease [78, 79]. Lowe et al. described a cohort of patients in whom 57% had osteoporosis, 11% 
had fragility fractures, and 14% had renal stones [80]. Amaral et al. compared normocalcemic 
to hypercalcemic PHPT patients. They found that 15% of normocalcemic patients had previ-
ous fractures compared to 10.8% of normocalcemic patients and the incidence of renal stones 
was 18.2 in normocalcemic vs. 18.9% of hypercalcemic patients [80]. Charopoulos et al. used 
peripheral quantitative CT to compare the effect of normocalcemic PHPT to the effect of hyper-
calcemic PHPT on volumetric BMD and bone geometry. They noted the catabolic effect on both 
groups although it is more severe in the hypercalcemic group. In the normocalcemic group, 
cortical properties were adversely affected, while the trabecular properties were preserved [80].
5.2. Natural history of bone disease in asymptomatic hyperparathyroidism
The natural history of bone loss in normocalcemic hyperparathyroidism is not fully defined. 
Lowe et al. showed decrease in BMD by at least 5% in 43% of the patients [80]. Koumakis 
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et al. measured BMD before and 12 months after PTx for patients with normocalcemic and 
hypercalcemic PHPT. Both groups showed statistically significant improvement of BMD at 
the postoperative measurement [14].
6. Treatment
6.1. Effect of surgery on the skeletal manifestations of hyperparathyroidism
Skeletal affection is among the indications of surgery in hyperparathyroidism. Even in asymp-
tomatic cases, surgery is suggested for perimenopausal or postmenopausal women and men 
50 years or older who have a T-score of −2.5 or less for any skeletal site. In premenopausal 
women and men under 50 years old, T-score of less than −2.5 is the cutoff for surgery. The 
presence of fragility fractures is also among the surgical indication [2, 4, 81].
Surgery improves the bone turnover marker and PTH level. Within the first year following sur-
gery, the BMD improves [70, 71, 82, 83]. This is due to uncoupling of bone resorption where the 
osteoclast stimulation by PTH stops, while bone formation continues [84]. Rubin et al. showed 
that the gain in BMD was sustainable up to 15 years following surgery at cortical and cancel-
lous sites despite of expected age-related losses in BMD. The increases in BMD were recorded 
in the study at years 1, 5, and 10 and showed that the lumbar spine increased to 9, 6, and 12%; 
the femoral neck 1, 7, and 10%; and the distal radius 4, 8, and 7% [70]. Christiansen et al. studied 
the BMD and bone turnover markers for the first 6 months after surgery. They reported that the 
bone turnover markers were normalized and increased bone density in regions rich in cancel-
lous bone but not cortical bone [82]. Similarly, Silverberg et al. noted improvement of BMD 
in lumbar spine and femoral neck but not the radius [71]. This may be explained by the fact 
that remodeling in cortical sites is slower than in trabecular bone. Thus, it takes a longer time 
for changes to be more pronounced [70]. Surgery also decreases the risk of fractures in hyper-
parathyroidism [72, 85, 86]. Vestergaard et al. demonstrated that the risk of fractures started to 
increase 10 years prior to surgery and reached its maximum 5–6 years following surgery. This 
risk falls back to normal after surgery [72]. Rudser et al. compared patients on dialysis who 
receive PTx to patients on dialysis without PTx. Fracture risks were lower among hemodialysis 
patients who underwent PTx compared to the dialysis patients who did not undergo PTx [84].
6.2. Effect of pharmacological treatment on skeletal manifestations of 
hyperparathyroidism
6.2.1. Bisphosphonates
Bisphosphonates (BP) are used in treatment of hyperparathyroidism as they act by inhibiting 
osteoclastic activity which is the cause of hypercalcemia and bone loss [2]. Several studies 
assessed the use of alendronate in hyperparathyroidism. Studies reported a reduction in the 
level of bone turnover markers and an increase in BMD. The increase in BMD was more for the 
trabecular than the cortical sites [87–92]. Although alendronate can lower the serum calcium 
initially, serum calcium tends to rise over 6 months, and the level of PTH may increase more 
than the pretreatment level [2, 90–93]. Pamidronate in several studies showed lowering of the 
serum calcium. However, due to limited time frame, no changes in BMD nor complications 
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were reported [94–100]. Clodronate use was associated with lowering of the serum calcium 
[101–103]. Several studies using clodronate reported lowering of urinary hydroxyproline and 
hence decreased bone turnover [101–103]. The use of risedronate in treatment of hyperparathy-
roidism was assessed in few studies [104, 105]. Tournis et al. reported that surgery is superior 
to risedronate as it improved the BMD and trabecular mineralization. Risedronate treatment in 
their study did not result in significant change in volumetric BMD or peripheral quantitative 
computed tomography [104]. A small number of studies reported the use of several BPs. Lee 
et al. reported the can prevent hungry bone syndrome among a very small number of patients 
[104]. Two other studies reported increase in BMD in the lumbar spine and hip [85, 106].
In conclusion, alendronate is the most studied BP in hyperparathyroidism. It decreases bone 
turnover and increased BMD. The effect of alendronate on serum calcium appears to be short 
lived.
6.2.2. Cinacalcet
This is a calcimimetic agent which increases the sensitivity of calcium-sensing receptors of the 
parathyroid gland to calcium, thus decreasing PTH secretion [107]. The effect of cinacalcet on 
bone turnover markers and BMD appears to be controversial. Several studies measured bone 
turnover markers with either decrease in the markers [108], no change [109, 110], or increase in 
the level of the markers [111, 112]. Similarly, the reported effects on BMD were an increase in 
BMD [113], a decrease [114], and no change [108, 111, 112]. Faggiano et al. compared cinacalcet 
monotherapy with cinacalcet with alendronate. The patients who received the combined ther-
apy had better improvement of BMD in lumbar spine and hip compared to the monotherapy 
group. There was no significant difference between biochemical changes in both groups [108]. 
Moe et al. studied the effect of cinacalcet in reducing the fracture risk in patients receiving 
hemodialysis. There was no significant effect of cinacalcet on fracture reduction in the intention-
to-treat analysis. However, a lag-sensoring analysis which took into consideration the crossover 
effect showed significant reduction of fracture risk in patients who received cinacalcet [84].
6.2.3. Vitamin D and calcium
Dietary calcium deficiency can induce elevation of PTH levels. Low vitamin D levels are asso-
ciated with increased bone turnover, deteriorated hip geometry, and lower BMD [68, 84, 115]. 
Patients with low calcium intake and PHPT who received calcium supplementation had lower 
levels of PTH and improved BMD of femoral neck [116]. For patients with vitamin D defi-
ciency, vitamin D repletion may decrease PTH levels and improved bone mineral density 
[116–118]. However, vitamin D supplementation may slightly increase serum calcium levels 
and urinary calcium excretion; thus, monitoring of calcium levels is valuable [81, 119, 120].
6.2.4. Other treatments of hyperparathyroidism which affect bone metabolism
Estrogen was found to improve BMD in women with hyperparathyroidism. The BMD of the 
lumbar spine and femoral neck increases, and bone turnover markers decrease with estrogen 
administration which has no or minimal effect on serum calcium [121, 122]. Raloxifene was 
also associated with improved BMD in PHPT [123, 124]. However, there is no data on the 
effect of estrogen or raloxifene on reducing the risk of fracture [120].
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Denosumab is a monoclonal antibody against RANKL that inhibits the binding of RANKL 
to RANK [125]. A study was conducted on patients with secondary hyperparathyroidism on 
dialysis in whom denosumab was administered. The BMD improved in the femoral neck and 
lumbar spine. However, a transient increase in PTH levels occurred in the patients.
7. Conclusion
Despite of the fact that many patients with hyperparathyroidism do not show symptoms of 
skeletal affection, clinicians always need to keep an eye on the catabolic effect of hyperpara-
thyroidism on the skeletal system. Better understanding of the mechanism of action of PTH of 
bone showed that many cells and mediators can influence the RANK/RANKL/OPG system, 
namely, T lymphocytes. Newer imaging modalities as TBS and HR-pQCT can be useful for 
detecting subtle bony changes. While parathyroidectomy is proven to reverse the skeletal 
effects of hyperparathyroidism, many patients may not be indicated for surgery, yet they 
should receive medical treatment that will protect them from the catabolic effect on the bone. 
Alendronate was extensively studied and showed to decrease bone turnover and increase 
BMD. Vitamin D supplementation for patients with vitamin D deficiency has a protective 
effect on the bone. Denosumab also has a protective effect, but clinical data about its use for 
patients with hyperparathyroidism is still limited.
Acknowledgement
I would like to thank Assistant Professor Stephen Mendelson (Assistant Professor in 
Department of Orthopedic Surgery in University of Pittsburgh, USA) and Professor Sherif 
Khaled (Professor of Orthopedic Surgery in Faculty of Medicine, Cairo University, Egypt) for 
their endless support to accomplish this work.
Conflict of interest
The author has no conflict of interests to declare.
Author details
Ahmed Khedr1,2*
*Address all correspondence to: ahmedkhedr@kasralainy.edu.eg
1 Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA
2 Department of Orthopedic Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt
Anatomy, Posture, Prevalence, Pain, Treatment and Interventions of Musculoskeletal Disorders96
References
[1] Malluche HH, Koszewski N, Monier-Faugere MC, Williams JP, Mawad H. Influence of 
the parathyroid glands on bone metabolism. European Journal of Clinical Investigation. 
2006;36(Suppl 2):23-33
[2] Elizabeth A, Streeten MAL. Hyperparathyroidism, primary. In: Martini L, editor. Ency-
clopedia of Endocrine Disease. Amsterdam: Elsevier; 2004. p. 558-566
[3] Habib Z, Camacho P. Primary hyperparathyroidism: An update. Current Opinion in 
Endocrinology, Diabetes, and Obesity. 2010;17(6):554-560
[4] Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet (London, 
England). 2017
[5] Civitelli R, Ziambaras K. Calcium and phosphate homeostasis: Concerted interplay of 
new regulators. Journal of Endocrinological Investigation. 2011;34(7 Suppl):3-7
[6] Silva BC, Bilezikian JP. Parathyroid hormone: Anabolic and catabolic actions on the skel-
eton. Current Opinion in Pharmacology. 2015;22:41-50
[7] Pacifici R. T cells, osteoblasts, and osteocytes: Interacting lineages key for the bone ana-
bolic and catabolic activities of parathyroid hormone. Annals of the New York Academy 
of Sciences. 2016;1364(1):11-24
[8] Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Moreno A, Dempster DW, et al. Short-term 
continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with 
decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 
mice. The Journal of Endocrinology. 2005;186(3):549-557
[9] Zhou H, Shen V, Dempster DW, Lindsay R. Continuous parathyroid hormone and estro-
gen administration increases vertebral cancellous bone volume and cortical width in the 
estrogen-deficient rat. Journal of Bone and Mineral Research. 2001;16(7):1300-1307
[10] Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, et al. On the 
mechanism of cancellous bone preservation in postmenopausal women with mild pri-
mary hyperparathyroidism. The Journal of Clinical Endocrinology and Metabolism. 
1999;84(5):1562-1566
[11] Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition 
of resorption on the anabolic response of bone to parathyroid hormone. Journal of Bone 
and Mineral Research. 1992;7(1):65-72
[12] Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, et al. Effect of 
parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal 
women with osteoporosis. The New England Journal of Medicine. 2001;344(19):1434-1441
[13] Nakchbandi IA, Lang R, Kinder B, Insogna KL. The role of the receptor activator of 
nuclear factor-κB ligand/osteoprotegerin cytokine system in primary hyperparathyroid-
ism. The Journal of Clinical Endocrinology and Metabolism. 2008;93(3):967-973
Skeletal Manifestations of Hyperparathyroidism
http://dx.doi.org/10.5772/intechopen.74034
97
[14] Koumakis E, Souberbielle J-C, Sarfati E, Meunier M, Maury E, Gallimard E, et al. Bone 
mineral density evolution after successful parathyroidectomy in patients with normo-
calcemic primary hyperparathyroidism. The Journal of Clinical Endocrinology and 
Metabolism. 2013;98(8):3213-3220
[15] Parfitt AM. Skeletal heterogeneity and the purposes of bone remodeling: Implications 
for the understanding of osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. 
Osteoporosis. 2nd ed. Florida: Academic Press; 2001. p. 433-477
[16] Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and impli-
cations for the pathogenesis and treatment of osteoporosis. Endocrine Reviews. 
2000;21(2):115-137
[17] Parfitt AM. Osteonal and hemi-osteonal remodeling: The spatial and temporal 
framework for signal traffic in adult human bone. Journal of Cellular Biochemistry. 
1994;55(3):273-286
[18] Owen M. The origin of bone cells in the postnatal organism. Arthritis and Rheumatism. 
1980;23(10):1073-1080
[19] Cho SW, Soki FN, Koh AJ, Eber MR, Entezami P, Park SI, et al. Osteal macrophages sup-
port physiologic skeletal remodeling and anabolic actions of parathyroid hormone in 
bone. Proceedings of the National Academy of Sciences of the United States of America. 
2014;111(4):1545-1550
[20] Lanske B, Amling M, Neff L, Guiducci J, Baron R, Kronenberg HM. Ablation of the 
PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone 
development. The Journal of Clinical Investigation. 1999;104(4):399-407
[21] Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, et al. 
Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteo-
blastic cells differentially affects cortical and trabecular bone. The Journal of Clinical 
Investigation. 2001;107(3):277-286
[22] Powell WF, Barry KJ, Tulum I, Kobayashi T, Harris SE, Bringhurst FR, et al. Targeted 
ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeo-
static calcemic responses. The Journal of Endocrinology. 2011;209(1):21-32
[23] Terauchi M, Li J-Y, Bedi B, Baek K-H, Tawfeek H, Galley S, et al. T lymphocytes 
amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell 
Metabolism. 2009;10(3):229-240
[24] Saini V, Marengi DA, Barry KJ, Fulzele KS, Heiden E, Liu X, et al. Parathyroid hor-
mone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates 
anabolic and catabolic skeletal responses to PTH. The Journal of Biological Chemistry. 
2013;288(28):20122-20134
[25] Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O’Brien CA. 
Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused 
by dietary calcium deficiency. Bone. 2014;66:146-154
Anatomy, Posture, Prevalence, Pain, Treatment and Interventions of Musculoskeletal Disorders98
[26] Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence 
for osteocyte regulation of bone homeostasis through RANKL expression. Nature 
Medicine. 2011;17(10):1231-1234
[27] Honma M, Ikebuchi Y, Kariya Y, Hayashi M, Hayashi N, Aoki S, et al. RANKL subcel-
lular trafficking and regulatory mechanisms in osteocytes. Journal of Bone and Mineral 
Research. 2013;28(9):1936-1949
[28] Szymczak J, Bohdanowicz-Pawlak A. Osteoprotegerin, RANKL, and bone turnover in 
primary hyperparathyroidism: The effect of parathyroidectomy and treatment with 
alendronate. Hormone and Metabolic Research. 2013;45(10):759-764
[29] O’Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone. 
2013;54(2):258-263
[30] Kanzawa M, Sugimoto T, Kanatani M, Chihara K. Involvement of osteoprotegerin/
osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by para-
thyroid hormone in mouse bone cells. European Journal of Endocrinology. 2000;142(6): 
661-664
[31] Lee S-K, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteo-
protegerin messenger ribonucleic acid expression in murine bone marrow cultures: 
Correlation with osteoclast-like cell formation 1. Endocrinology. 1999;140(8):3552-3561
[32] Khosla S. Minireview: The OPG/RANKL/RANK system. Endocrinology. 2001;142(12): 
5050-5055
[33] Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. 
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhib-
itory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy 
of Sciences of the United States of America. 1998;95(7):3597-3602
[34] Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient 
for osteoblast-mediated activation of bone resorption in osteoclasts. The Journal of 
Experimental Medicine. 1998;188(5):997-1001
[35] Simonet WS, Lacey D, Dunstan CR, Kelley MCMS, Chang M, Lüthy R, et al. Osteo-
protegerin: A novel secreted protein involved in the regulation of bone density. Cell. 
1997;89(2):309-319
[36] Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κB ligand 
and osteoprotegerin regulation of bone remodeling in health and disease. Endocrine 
Reviews. 2008;29(2):155-192
[37] Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, et al. Catabolic effects of con-
tinuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL 
and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 
2001;142(9):4047-4054
[38] Fu Q, Jilka RL, Manolagas SC, O’Brien CA. Parathyroid hormone stimulates receptor 
activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase 
A activation of cAMP-response element-binding protein. The Journal of Biological 
Chemistry. 2002;277(50):48868-48875
Skeletal Manifestations of Hyperparathyroidism
http://dx.doi.org/10.5772/intechopen.74034
99
[39] Lee S-K, Lorenzo JA. Regulation of receptor activator of nuclear factor-kappa B ligand 
and osteoprotegerin mRNA expression by parathyroid hormone is predominantly 
mediated by the protein kinase a pathway in murine bone marrow cultures. Bone. 
2002;31(1):252-259
[40] Kondo H, Guo J, Bringhurst FR. Cyclic adenosine monophosphate/protein kinase A 
mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation 
of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow 
stromal cells. Journal of Bone and Mineral Research. 2002;17(9):1667-1679
[41] Pacifici R. Osteoimmunology and its implications for transplantation. American Journal 
of Transplantation. 2013;13(9):2245-2254
[42] Di Rosa F. T-lymphocyte interaction with stromal, bone and hematopoietic cells in the 
bone marrow. Immunology and Cell Biology. 2009;87(1):20-29
[43] Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 
stimulates the production and expression of proinflammatory cytokines, IL-beta and 
TNF-alpha, by human macrophages. Journal of Immunology. 1998;160(7):3513-3521
[44] Waisman A. T helper cell populations: As flexible as the skin? European Journal of 
Immunology. 2011;41(9):2539-2543
[45] Komatsu N, Takayanagi H. Autoimmune arthritis: The interface between the immune 
system and joints. Advances in Immunology. 2012:45-71
[46] Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 func-
tions as an osteoclastogenic helper T cell subset that links T cell activation and bone 
destruction. The Journal of Experimental Medicine. 2006;203(12):2673-2682
[47] Adamopoulos IE, Chao C-C, Geissler R, Laface D, Blumenschein W, Iwakura Y, et al. 
Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. 
Arthritis Research & Therapy. 2010;12(1):R29
[48] Koh AJ, Novince CM, Li X, Wang T, Taichman RS, McCauley LK. An irradiation-altered 
bone marrow microenvironment impacts anabolic actions of PTH. Endocrinology. 
2011;152(12):4525-4536
[49] Löwik CW, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OL, Aarden LA, et al. 
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 pro-
duction by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis. 
Biochemical and Biophysical Research Communications. 1989;162(3):1546-1552
[50] Basu R, Hatton RD, Weaver CT. The Th17 family: Flexibility follows function. 
Immunological Reviews. 2013;252(1):89-103
[51] Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental 
pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 
2006;441(7090):235-238
[52] Martinez GJ, Nurieva RI, Yang XO, Dong C. Regulation and function of proinflamma-
tory TH17 cells. Annals of the New York Academy of Sciences. 2008;1143(1):188-211
Anatomy, Posture, Prevalence, Pain, Treatment and Interventions of Musculoskeletal Disorders100
[53] Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hor-
mone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of 
pre/osteoclasts. The Journal of Biological Chemistry. 2007;282(45):33098-33106
[54] Tamasi JA, Vasilov A, Shimizu E, Benton N, Johnson J, Bitel CL, et al. Monocyte chemoat-
tractant protein-1 is a mediator of the anabolic action of parathyroid hormone on bone. 
Journal of Bone and Mineral Research. 2013;28(9):1975-1986
[55] Patel H, Trooskin S, Shapses S, Sun W, Wang X. Serum monocyte chemokine protein-1 
levels before and after parathyroidectomy in patients with primary hyperparathyroid-
ism. Endocrine Practice. 2014;20(11):1165-1169
[56] Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, et al. Current 
issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings 
of the Fourth International Workshop. The Journal of Clinical Endocrinology and 
Metabolism. 2014;99(10):3580-3594
[57] Zhao L, Liu J-M, He X-Y, Zhao H-Y, Sun L-H, Tao B, et al. The changing clinical patterns 
of primary hyperparathyroidism in Chinese patients: Data from 2000 to 2010 in a single 
clinical center. The Journal of Clinical Endocrinology and Metabolism. 2013;98(2):721-728
[58] Bandeira F, Cusano NE, Silva BC, Cassibba S, Almeida CB, Machado VCC, et al. Bone 
disease in primary hyperparathyroidism. Arquivos Brasileiros de Endocrinologia e 
Metabologia. 2014;58(5):553-561
[59] Bandeira F, Griz L, Caldas G, Bandeira C, Freese E. From mild to severe primary hyper-
parathyroidism: The Brazilian experience. Arquivos Brasileiros de Endocrinologia e 
Metabologia. 2006;50(4):657-663
[60] Brasier AR, Nussbaum SR. Hungry bone syndrome: Clinical and biochemical predic-
tors of its occurrence after parathyroid surgery. The American Journal of Medicine. 
1988;84(4):654-660
[61] Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: 
How and why? Clinical and Experimental Nephrology. 2017;21(S1):37-45
[62] Vu TDT, Wang XF, Wang Q, Cusano NE, Irani D, Silva BC, et al. New insights into the 
effects of primary hyperparathyroidism on the cortical and trabecular compartments of 
bone. Bone. 2013;55(1):57-63
[63] Hansen S, Beck Jensen J-E, Rasmussen L, Hauge EM, Brixen K. Effects on bone geom-
etry, density, and microarchitecture in the distal radius but not the tibia in women with 
primary hyperparathyroidism: A case-control study using HR-pQCT. Journal of Bone 
and Mineral Research. 2010;25(9):1941-1947
[64] Stein EM, Silva BC, Boutroy S, Zhou B, Wang J, Udesky J, et al. Primary hyperparathy-
roidism is associated with abnormal cortical and trabecular microstructure and reduced 
bone stiffness in postmenopausal women. Journal of Bone and Mineral Research. 
2013;28(5):1029-1040
Skeletal Manifestations of Hyperparathyroidism
http://dx.doi.org/10.5772/intechopen.74034
101
[65] Roux JP, Wegrzyn J, Boutroy S, Bouxsein ML, Hans D, Chapurlat R. The predictive value 
of trabecular bone score (TBS) on whole lumbar vertebrae mechanics: An ex vivo study. 
Osteoporosis International. 2013;24(9):2455-2460
[66] Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg M-A. Correlations 
between trabecular bone score, measured using anteroposterior dual-energy X-ray 
absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: 
An experimental study on human cadaver vertebrae. Journal of Clinical Densitometry. 
2011;14(3):302-312
[67] Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, et al. Trabecular bone 
score: A noninvasive analytical method based upon the DXA image. Journal of Bone and 
Mineral Research. 2014;29(3):518-530
[68] Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde 
L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. 
Clinical Endocrinology. 2008;68(5):707-715
[69] Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in 
patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. The 
Journal of Clinical Endocrinology and Metabolism. 2005;90(4):2122-2126
[70] Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural 
history of primary hyperparathyroidism with or without parathyroid surgery after 15 
years. The Journal of Clinical Endocrinology and Metabolism. 2008;93(9):3462-3470
[71] Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of 
primary hyperparathyroidism with or without parathyroid surgery. The New England 
Journal of Medicine. 1999;341(17):1249-1255
[72] Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. 
Cohort study of risk of fracture before and after surgery for primary hyperparathyroid-
ism. BMJ. 2000;321(7261):598-602
[73] Khosla S, Melton LJ, Wermers RA, Crowson CS, O’Fallon WM, Riggs BL. Primary hyper-
parathyroidism and the risk of fracture: A population-based study. Journal of Bone and 
Mineral Research. 1999;14(10):1700-1707
[74] Romagnoli E, Cipriani C, Nofroni I, Castro C, Angelozzi M, Scarpiello A, et al. “Trabecular 
bone score” (TBS): An indirect measure of bone micro-architecture in postmenopausal 
patients with primary hyperparathyroidism. Bone. 2013;53(1):154-159
[75] Eller-Vainicher C, Filopanti M, Palmieri S, Ulivieri FM, Morelli V, Zhukouskaya VV, 
et al. Bone quality, as measured by trabecular bone score, in patients with primary 
hyperparathyroidism. European Journal of Endocrinology. 2013;169(2):155-162
[76] Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of sur-
gery versus no surgery in patients with mild asymptomatic primary hyperparathyroid-
ism. The Journal of Clinical Endocrinology and Metabolism. 2004;89(11):5415-5422
Anatomy, Posture, Prevalence, Pain, Treatment and Interventions of Musculoskeletal Disorders102
[77] Hansen S, Hauge EM, Rasmussen L, Jensen J-EB, Brixen K. Parathyroidectomy 
improves bone geometry and microarchitecture in female patients with primary 
 hyperparathyroidism: A one-year prospective controlled study using high-resolution 
peripheral quantitative computed tomography. Journal of Bone and Mineral Research. 
2012;27(5):1150-1158
[78] Silverberg SJ, Bilezikian JP. “Incipient” primary hyperparathyroidism: A “forme fruste” 
of an old disease. The Journal of Clinical Endocrinology and Metabolism. 2003;88(11): 
5348-5352
[79] Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathy-
roidism: Evidence for a generalized target-tissue resistance to parathyroid hormone. The 
Journal of Clinical Endocrinology and Metabolism. 2003;88(10):4641-4648
[80] Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary 
hyperparathyroidism: Further characterization of a new clinical phenotype. The Journal 
of Clinical Endocrinology and Metabolism. 2007;92(8):3001-3005
[81] Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. 
Guidelines for the management of asymptomatic primary hyperparathyroidism: 
Summary statement from the Fourth International Workshop. The Journal of Clinical 
Endocrinology and Metabolism. 2014;99(10):3561-3569
[82] Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, et al. Medical 
observation, compared with parathyroidectomy, for asymptomatic primary hyperpara-
thyroidism: A prospective, randomized trial. The Journal of Clinical Endocrinology and 
Metabolism. 2007;92(5):1687-1692
[83] Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L, et al. Primary 
hyperparathyroidism: Short-term changes in bone remodeling and bone mineral density 
following parathyroidectomy. Bone. 1999;25(2):237-244
[84] Lee JH, Kim JH, Hong AR, Kim SW, Shin CS. Skeletal effects of vitamin D deficiency 
among patients with primary hyperparathyroidism. Osteoporosis International. 
2017;28(5):1667-1674
[85] Yeh MW, Zhou H, Adams AL, Ituarte PHG, Li N, Liu I-LA, et al. The relationship of 
parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathy-
roidism: An observational study. Annals of Internal Medicine. 2016;164(11):715-723
[86] Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathy-
roidectomy among chronic hemodialysis patients. Journal of the American Society of 
Nephrology. 2007;18(8):2401-2407
[87] Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, et al. Alendronate 
in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial. 
The Journal of Clinical Endocrinology and Metabolism. 2004;89(7):3319-3325
[88] Khan A, Bilezikian J, Kung A, Dubois S, Standish T, Syed Z. Alendronate therapy in men 
with primary hyperparathyroidism. Endocrine Practice. 2009;15(7):705-713
Skeletal Manifestations of Hyperparathyroidism
http://dx.doi.org/10.5772/intechopen.74034
103
[89] Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, et al. Effects of 
alendronate and vitamin D in patients with normocalcemic primary hyperparathyroid-
ism. Osteoporosis International. 2015;26(4):1295-1302
[90] Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of pri-
mary hyperparathyroid-related osteoporosis: A 2-year study. The Journal of Clinical 
Endocrinology and Metabolism. 2002;87(10):4482-4489
[91] Akbaba G, Isik S, Ates Tutuncu Y, Ozuguz U, Berker D, Guler S. Comparison of alen-
dronate and raloxifene for the management of primary hyperparathyroidism. Journal 
of Endocrinological Investigation. 2013;36(11):1076-1082
[92] Chow CC, Chan WB, Li JKY, Chan NN, Chan MHM, Ko GTC, et al. Oral alendronate 
increases bone mineral density in postmenopausal women with primary hyperpara-
thyroidism. The Journal of Clinical Endocrinology and Metabolism. 2003;88(2):581-587
[93] Adami S, Mian M, Bertoldo F, Rossini M, Jayawerra P, O’Riordan JL, et al. Regulation 
of calcium-parathyroid hormone feedback in primary hyperparathyroidism: Effects of 
bisphosphonate treatment. Clinical Endocrinology. 1990;33(3):391-397
[94] Phitayakorn R, McHenry CR. Hyperparathyroid crisis: Use of bisphosphonates 
as a bridge to parathyroidectomy. Journal of the American College of Surgeons. 
2008;206(6):1106-1115
[95] Jansson S, Morgan E. Biochemical effects from treatment with bisphosphonate and 
surgery in patients with primary hyperparathyroidism. World Journal of Surgery. 
2004;28(12):1293-1297
[96] Ammann P, Herter-Clavel C, Lubrano A, Rizzoli R. A single bisphosphonate infusion 
is associated with improved functional capacity in elderly subjects with primary hyper-
parathyroidism. Aging Clinical and Experimental Research. 2003;15(6):500-504
[97] Schmidli RS, Wilson I, Espiner EA, Richards AM, Donald RA. Aminopropylidine 
diphosphonate (APD) in mild primary hyperparathyroidism: Effect on clinical status. 
Clinical Endocrinology. 1990;32(3):293-300
[98] Ishimura E, Miki T, Koyama H, Harada K, Nakatsuka K, Inaba M, et al. Effect of amino-
hydroxypropylidene diphosphonate on the bone metabolism of patients with parathy-
roid adenoma. Hormone and Metabolic Research. 1993;25(9):493-497
[99] Jansson S, Tisell LE, Lindstedt G, Lundberg PA. Disodium pamidronate in the pre-
operative treatment of hypercalcemia in patients with primary hyperparathyroidism. 
Surgery. 1991;110(3):480-486
[100] van Breukelen FJ, Bijvoet OL, Frijlink WB, Sleeboom HP, Mulder H, van Oosterom AT. 
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: Observations 
on regulation of serum calcium. Calcified Tissue International. 1982;34(4):321-327
[101] Hamdy NA, Gray RE, McCloskey E, Galloway J, Rattenbury JM, Brown CB, et al. 
Clodronate in the medical management of hyperparathyroidism. Bone. 1987;8(Suppl 1): 
S69-S77
Anatomy, Posture, Prevalence, Pain, Treatment and Interventions of Musculoskeletal Disorders104
[102] Douglas DL, Kanis JA, Paterson AD, Beard DJ, Cameron EC, Watson ME, et al. Drug 
treatment of primary hyperparathyroidism: Use of clodronate disodium. British 
Medical Journal (Clinical Research Ed.). 1983;286(6365):587-590
[103] Shane E, Baquiran DC, Bilezikian JP. Effects of dichloromethylene diphosphonate 
on serum and urinary calcium in primary hyperparathyroidism. Annals of Internal 
Medicine. 1981;95(1):23-27
[104] Tournis S, Fakidari E, Dontas I, Liakou C, Antoniou J, Galanos A, et al. Effect of para-
thyroidectomy versus risedronate on volumetric bone mineral density and bone geom-
etry at the tibia in postmenopausal women with primary hyperparathyroidism. Journal 
of Bone and Mineral Metabolism. 2014;32(2):151-158
[105] Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR. Acute changes in calcium 
homeostasis during treatment of primary hyperparathyroidism with risedronate. The 
Journal of Clinical Endocrinology and Metabolism. 1993;77(4):1067-1071
[106] Segula D, Nikolova T, Marks E, Ranganath L, Mishra V. Long term outcome of bisphos-
phonate therapy in patients with primary hyperparathyroidism. International Journal 
of Clinical Medicine. 2014;5(14):829-835
[107] Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, et al. 
Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. The Journal 
of Pharmacology and Experimental Therapeutics. 2004;308(2):627-635
[108] Faggiano A, Di Somma C, Ramundo V, Severino R, Vuolo L, Coppola A, et al. 
Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia 
and improves bone mineral density in patients with primary hyperparathyroidism. 
Endocrine. 2011;39(3):283-287
[109] Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S, et al. Cinacalcet 
efficacy in patients with moderately severe primary hyperparathyroidism according 
to the European medicine agency prescription labeling. Journal of Endocrinological 
Investigation. 2012;35(7):655-660
[110] Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, Faggiano A, et al. Cinacalcet ther-
apy in patients affected by primary hyperparathyroidism associated to multiple endo-
crine neoplasia syndrome type 1 (MEN1). Endocrine. 2016;52(3):495-506
[111] Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydro-
chloride maintains long-term normocalcemia in patients with primary hyperparathy-
roidism. The Journal of Clinical Endocrinology and Metabolism. 2005;90(1):135-141
[112] Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, et al. 
Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone den-
sitometric outcomes in a five-year study. The Journal of Clinical Endocrinology and 
Metabolism. 2009;94(12):4860-4867
[113] Keutgen XM, Buitrago D, Filicori F, Kundel A, Elemento O, Fahey TJ, et al. Calcimimetics 
versus parathyroidectomy for treatment of primary hyperparathyroidism: Retrospective 
chart analysis of a prospective database. Annals of Surgery. 2012;255(5):981-985
Skeletal Manifestations of Hyperparathyroidism
http://dx.doi.org/10.5772/intechopen.74034
105
[114] Norman J, Lopez J, Politz D. Cinacalcet (Sensipar) provides no measurable clinical ben-
efits for patients with primary hyperparathyroidism and may accelerate bone loss with 
prolonged use. Annals of Surgical Oncology. 2012;19(5):1466-1471
[115] Stein EM, Dempster DW, Udesky J, Zhou H, Bilezikian JP, Shane E, et al. Vitamin D 
deficiency influences histomorphometric features of bone in primary hyperparathy-
roidism. Bone. 2011;48(3):557-561
[116] Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation 
to patients with primary hyperparathyroidism and a low calcium intake. European 
Journal of Nutrition. 2002;41(6):258-263
[117] Rolighed L, Bollerslev J, Mosekilde L. Vitamin D treatment in primary hyperparathy-
roidism. Current Drug Safety. 2011;6(2):100-107
[118] Walker MD, Cong E, Lee JA, Kepley A, Zhang C, McMahon DJ, et al. Vitamin D in pri-
mary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presen-
tation. The Journal of Clinical Endocrinology and Metabolism. 2015;100(9):3443-3451
[119] Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current 
evidence for recommendation of surgery, medical treatment and vitamin D reple-
tion in mild primary hyperparathyroidism. European Journal of Endocrinology. 
2011;165(6):851-864
[120] Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, et al. Primary 
hyperparathyroidism: Review and recommendations on evaluation, diagnosis, and 
management. A Canadian and international consensus. Osteoporosis International. 
2017;28(1):1-19
[121] Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replace-
ment therapy on bone mineral density in postmenopausal women with mild primary 
hyperparathyroidism. A randomized, controlled trial. Annals of Internal Medicine. 
1996;125(5):360-368
[122] Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of pri-
mary hyperparathyroidism in postmenopausal women. The New England Journal of 
Medicine. 1986;314(23):1481-1485
[123] Zanchetta JR, Bogado CE. Raloxifene reverses bone loss in postmenopausal women 
with mild asymptomatic primary hyperparathyroidism. Journal of Bone and Mineral 
Research. 2001;16(1):189-190
[124] Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and 
markers of bone turnover in postmenopausal women with primary hyperparathyroid-
ism. The Journal of Clinical Endocrinology and Metabolism. 2003;88(3):1174-1178
[125] Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, et al. Denosumab 
mimics the natural decoy receptor osteoprotegerin by interacting with its major bind-
ing site on RANKL. Oncotarget. 2014;5(16):6647-6653
Anatomy, Posture, Prevalence, Pain, Treatment and Interventions of Musculoskeletal Disorders106
